eess.IVNov 2, 2026

A Novel Conditional Adversarial Diffusion Model for High-Fidelity OCT-to-OCT Image Translation and Precise Anti-VEGF Therapy Response Prediction in Diabetic Macular Edema

Authors: Reza Rasti, Armin Biglari, Sobhan Mohammadi Hafshejani, Alireza Dehghani, Michael J. Allingham, Sina Farsiu

Organizations: Department of Biomedical Engineering, Faculty of Engineering, University of Isfahan, Isfahan, Iran · VIP Lab, Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA · Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran · Department of Ophthalmology, Duke University School of Medicine, Durham, NC 27708, USA · 

Abstract

Diabetic macular edema (DME) is a leading cause of severe vision loss among working-age adults. Although intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections currently serve as the first-line therapy for DME, a notable subset of patients fails to respond despite the substantial cost and clinical burden, suggesting they may benefit more from alternative interventions. Automated, noninvasive pre-treatment response assessment could therefore spare non-responders from the current trial-and-error treatment paradigm. In this study, we propose a novel conditional adversarial diffusion framework that synthesizes post-treatment optical coherence tomography (OCT) images from baseline scans, enabling the derivation of each patient's initial response to anti-VEGF therapy. The model was developed with subject-level 5-fold cross-validation on a US cohort (n = 127) and externally validated on an independent Iranian cohort (n = 44). Benchmarked against fourteen baseline and state-of-the-art translation models, the proposed model achieved the best treatment-response prediction performance among the methods evaluated for that task on both cohorts, with balanced accuracies of 85.7% and 93.0% on the US cohort and 85.2% and 95.3% on the external Iranian cohort at the 10% and 20% central subfield thickness reduction thresholds, respectively. Ultimately, this framework offers a decision-support tool to help ophthalmologists anticipate initial anti-VEGF outcomes in DME prior to treatment initiation, toward personalized therapy selection. The source code will be made publicly available upon acceptance.

Explore similar work

May 30, 2026

Response-Aware Multimodal Learning for Post-Treatment Visual Acuity Forecasting

Long-term visual acuity (VA) outcomes after anti-VEGF therapy are central to patient counseling, expectation setting, and follow-up planning in diabetic macular edema (DME). However, in clinical practice, physicians must often estimate long-term visual trajectories based only on early post-treatment findings, making reliable prognostication difficult. Although prior OCT-based learning approaches have largely focused on short-term response or single-endpoint prediction, modeling VA trajectories across multiple future time points from early longitudinal observations remains insufficiently explored. In this study, we assembled a real-world cohort of 188 anti-VEGF--treated DME patients with paired baseline and month-1 OCT scans, along with tabular OCT-derived biomarkers and non-imaging clinical variables. Using only these early data, we formulate a multi-horizon VA forecasting problem aimed at predicting visual outcomes at 3, 6, 12, 18, and 24 months, reflecting clinically meaningful follow-up intervals. We propose ReVA, a response-aware multimodal framework that integrates structural features from baseline and month-1 OCT with the tabular variables to capture baseline disease status and early treatment response. ReVA uses spatial attention to preserve localized prognostic imaging features and a dependency-aware tabular encoder to model interactions among clinical variables. These multimodal representations are fused to predict patient-specific long-term visual acuity trajectories. The proposed framework achieves MAE =0.1246=0.1246, RMSE =0.1621=0.1621, and R2=0.6064R^2=0.6064 for 24-month VA prediction, with consistent performance across all forecast horizons. Our findings show that incorporating early treatment-response signals enables clinically meaningful long-term visual acuity forecasting, supporting data-driven decision support for routine anti-VEGF management.
Aug 27, 2026

Automated 2D and 3D Segmentation of AMD and DME Lesions in OCT

Age-related macular degeneration (AMD) and diabetic macular edema (DME) are leading causes of vision loss, and optical coherence tomography (OCT) is the standard modality for detecting and monitoring the subtle lesions that drive treatment decisions. Most deep-learning segmentation work for OCT is validated only in-domain, leaving generalization to clinical data collected under different acquisition protocols largely untested. This work develops and systematically ablates four lesion-segmentation pipelines -- 2D and 3D variants for AMD and DME -- reaching Dice scores of 0.76 to 0.82 with strong volumetric and surface calibration (r vol, r surf greater than or equal to 0.97 across all four pipelines) on an in-domain validation set. The ablation process establishes a full-volume, calibration-aware adoption standard that catches mechanisms an ordinary slice-level evaluation would keep, and identifies ensemble composition as the most consistent driver of improvement. To test generalization, the models are evaluated on OLIVES, an external clinical cohort with no lesion-level ground truth, using a proxy-metric framework built around biomarker AUROC, central subfield thickness (CST) correlation, and longitudinal concordance. Predictions track clinical biomarkers outside the training distribution, though less strongly than in-domain -- evidence for, not validation of, automated lesion-burden tracking as a clinical tool.
Jun 20, 2026

OphthaDT: Generative Digital Twins for Forecasting Visual Acuity Trajectories in Ophthalmology

Precision medicine in ophthalmology requires accurate longitudinal predictions, but the fragmented nature of multimodal clinical data remains a barrier to forecasting. We introduce OphthaDT, an LLM-based digital twin for ophthalmology that serializes longitudinal patient histories from 3,220 patients across four Phase III clinical trials into structured narratives to forecast best corrected visual acuity (BCVA). In benchmarks spanning up to 100 weeks, OphthaDT demonstrated the lowest prediction error in neovascular age-related macular degeneration (nAMD), achieving an average mean absolute error (MAE) reduction of 6.0% compared to all baselines. In diabetic macular edema (DME), OphthaDT demonstrated competitive performance against all baselines while outperforming Random Forest and XGBoost by an average MAE reduction of 2.6% and 6.9%, respectively. Results reveal that OphthaDT's predictive advantage scales with trajectory complexity: whereas linear models remain effective for the more stable treatment responses of DME, OphthaDT's capacity is better suited for capturing the high longitudinal variability of nAMD. Finally, OphthaDT handles irregular sampling without imputation, positioning LLM-based clinical trajectory modeling as a methodology that could reduce patient burden and accelerate drug development.